Physician profile
Michael Levine
NPI 1447232202
$628,517.19
in general payments reported to CMS, 2019-2025
17 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $83K · 2021: $109K · 2022: $124K · 2023: $133K · 2024: $95K · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $222K · Food and Beverage: $2,978 · Travel and Lodging: $2,438 · Consulting Fee: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $221,558.48 |
| Food and Beverage | $2,978.40 |
| Travel and Lodging | $2,438.00 |
| Consulting Fee | $1,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Encore Medical, Lp | $615,288.61 | 2019-2024 | Djo Surgical |
| Exactech, INC. | $4,334.01 | 2019-2024 | |
| Spineguard, INC. | $2,250.00 | 2022-2025 | |
| Zimmer Biomet Holdings, INC. | $1,506.89 | 2019-2024 | Persona, Comprehensive Shoulder System |
| Depuy Synthes Sales INC. | $1,243.35 | 2021-2024 | Attune |
| Innovation Technologies INC | $1,141.56 | 2019-2025 | Irrisept |
| Pacira Pharmaceuticals Incorporated | $1,132.12 | 2024 | Iovera |
| Next Science LLC | $476.90 | 2022-2023 | Blastx, Xperience, Surgx |
| Stryker Corporation | $428.82 | 2021-2025 | Mako, 7 X 23mm Citrelock Implant |
| Amgen INC. | $382.48 | 2021-2023 | |
| Vericel Corporation | $124.99 | 2019 | |
| Heron Therapeutics, INC. | $53.00 | 2023 | Zynrelef |
| Pacira Therapeutics, INC. | $49.92 | 2019 | |
| Bioventus LLC | $46.54 | 2025 | Gelsyn-3 |
| Medical Device Business Services, INC. | $42.82 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $15.18 | 2025 | Euflexxa |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.